Chemoinformaics analysis of 6-O-(e)-p-coumaroyl glucopyranose
| Molecular Weight | 326.301 | nRot | 4 |
| Heavy Atom Molecular Weight | 308.157 | nRig | 12 |
| Exact Molecular Weight | 326.1 | nRing | 2 |
| Solubility: LogS | -4.347 | nHRing | 1 |
| Solubility: LogP | 4.512 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 41 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 23 | No. of Aromatic Carbocycles | 1 |
| nHetero | 8 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 18 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 8 | No. of Arom Bond | 6 |
| nHA | 8 | APOL | 43.4683 |
| nHD | 5 | BPOL | 22.3977 |
| QED | 0.739 |
| Synth | 4.352 |
| Natural Product Likeliness | 3.071 |
| NR-PPAR-gamma | 0.007 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.515 |
| Pgp-sub | 0 |
| HIA | 0.012 |
| CACO-2 | -4.627 |
| MDCK | 0.0000114 |
| BBB | 0.784 |
| PPB | 0.92087 |
| VDSS | 1.163 |
| FU | 0.10602 |
| CYP1A2-inh | 0.019 |
| CYP1A2-sub | 0.391 |
| CYP2c19-inh | 0.122 |
| CYP2c19-sub | 0.916 |
| CYP2c9-inh | 0.205 |
| CYP2c9-sub | 0.586 |
| CYP2d6-inh | 0.022 |
| CYP2d6-sub | 0.299 |
| CYP3a4-inh | 0.765 |
| CYP3a4-sub | 0.414 |
| CL | 7.669 |
| T12 | 0.103 |
| hERG | 0.012 |
| Ames | 0.009 |
| ROA | 0.03 |
| SkinSen | 0.138 |
| Carcinogencity | 0.021 |
| EI | 0.714 |
| Respiratory | 0.667 |
| NR-Aromatase | 0.587 |
| Antiviral | Yes |
| Prediction | 0.759457 |